GLAUKOS CORP (GKOS) Covered Calls

You can sell covered calls on GLAUKOS CORP to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GKOS (prices last updated Thu 4:16 PM ET):

GLAUKOS CORP (GKOS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
59.47 +2.36 55.00 75.00 417K - 2.1B
Covered Calls For GLAUKOS CORP (GKOS)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 21 60 2.50 72.50 -17.2% -169.7%
Jan 18 60 3.50 71.50 -16.1% -90.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. Glaukos Corporation markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. The company was founded in 1998 and is headquartered in San Clemente, California.